Clinical Trials in Surgical Oncology

Published:November 03, 2022DOI:
      Figure thumbnail fx1
      Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, FACS, FSSO, FRACS (Hon.), Consulting Editor
      The issue covers a range of important topics related to clinical trials. In particular, this issue highlights the fundamentals of conducting cooperative trials and how to leverage national trial networks as well as touches on investigator-initiated trials. In addition to these cross-cutting topics, the authors also provide a contemporary state-of-the-art update on clinical trials across a wide range of oncologic diseases. In particular, the team of expert coauthors provides data from clinical trials related to tumors, including breast cancer, melanoma, esophageal and gastric cancer, as well as hepatopancreaticobiliary malignancies, colorectal cancer, sarcoma, and neuroendocrine tumors. In addition, the important topic of diversity, equity, and inclusion in clinical trials is highlighted.
      I wish to express my sincere gratitude to Dr Ahmad and Dr Maithel for their efforts to identify such a wonderful group of leaders in the field of clinical trials. These expert authors have done an incredible job emphasizing the various aspects of clinical trials as well as describing cancer-specific clinical trial data that will prove helpful to both trainees and faculty. I know that this issue of Surgical Oncology Clinics of North America will serve cancer providers well in acquainting them with the latest up-to-date data on clinical trials in oncology. I would like to thank Dr Ahmad and Dr Maithel and all the expert authors again for an outstanding issue of the Surgical Oncology Clinics of North America.